
Spirit AeroSystems Holdings Inc
Aerospace & Defense
Spirit AeroSystems Holdings Inc (SPR) Stock News
The latest SPR headlines and market coverage — 5 recent stories, updated throughout the day.
- The Motley Fool·
CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential
CRISPR Therapeutics trades at a significant discount despite Wall Street analysts rating 58% as buy with 437% upside potential. The company's first commercialized product, Casgevy, treats sickle cell disease and beta thalassemia. With only 64 patients treated in 2025 and $4.1M in sales, analysts project revenue growth to $43.9M in 2026 and $151.6M in 2027. A strong pipeline of five additional therapies in clinical trials and a large addressable market of 60,000 eligible patients position CRISPR as a potential long-term growth opportunity, though highly speculative.
- The Motley Fool·
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
CRISPR Therapeutics acquired CTX611, a clinical-stage siRNA therapy targeting Factor XI for blood clot prevention, for $95 million upfront. The program could significantly impact the company's revenue despite being a follower in a competitive anticoagulant market dominated by Eliquis and other therapies. With only $1.4 million in Q1 2026 revenue, success with CTX611 could be transformative for the stock.
- The Motley Fool·
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has FDA-approved CASGEVY therapy and stronger financials, versus Editas Medicine, which focuses on in vivo gene editing but lacks FDA approval and has a weaker balance sheet. CRISPR Therapeutics is recommended as the better 2026 investment due to its commercial-stage advantage, stronger cash position, and lower financial risk, despite Editas offering potentially greater upside if successful.
- The Motley Fool·
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has an approved product (Casgevy) and a deeper pipeline, versus Beam Therapeutics, a clinical-stage company with a potentially safer base-editing platform. CRISPR Therapeutics is recommended as the better investment due to its approved product, stronger cash position ($2.4B vs $1.2B), and deeper pipeline, making it less risky despite both stocks carrying clinical trial risks.
- The Motley Fool·
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?
CRISPR Therapeutics has bullish analyst sentiment with Piper Sandler's Edward Tenthoff setting a $110 price target, implying over 100% upside. The biotech's prospects are supported by upcoming clinical trial data for CTX611 (an anticoagulant targeting a $20B market), expansion of its approved Casgevy gene therapy to children, and a deep pipeline. However, the stock remains risky due to dependence on positive clinical results and execution.